PMID: 2500346Jan 1, 1989Paper

Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism

European Journal of Clinical Pharmacology
H WietholtzS Matern

Abstract

Three groups of non-smoking epileptic patients without liver disease receiving antiepileptic monotherapy have been compared with 10 healthy non-smoking volunteers. Group 1 received phenytoin (n = 10), Group 2 carbamazepine (n = 10) and Group 3 valproic acid (n = 6). Cytochrome P-450 activity was monitored by measuring urinary 6-beta-hydroxycortisol output and systemic antipyrine clearance. Both, 6-beta-hydroxycortisol output and antipyrine clearance were significantly enhanced in patients on phenytoin and carbamazepine, but not in those on valproic acid. On the other hand, phenytoin alone increased the clearance of caffeine from 1.5 (controls) to 3.6 ml.min-1.kg-1, and reduced its half life from 4.8 to 2.4 h. Carbamazepine and valproic acid had no effect on caffeine metabolism. The results are in keeping with the well known heterogeneity of the hepatic monooxygenase system, as phenytoin and carbamazepine induce different panels of cytochrome P-450 isoenzymes. Phenytoin treatment may impair the validity of the caffeine liver function test.

References

Sep 1, 1979·Clinical Pharmacology and Therapeutics·E S Vesell
Jul 1, 1978·Clinical Pharmacology and Therapeutics·W D Parsons, A H Neims
Oct 1, 1978·Journal of Steroid Biochemistry·B K Park
Oct 1, 1976·Clinical Pharmacology and Therapeutics·J BircherR Preisig
May 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R JoeresE Richter
Jan 1, 1988·European Journal of Clinical Pharmacology·T Zysset, H Wietholtz
Mar 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G JostR Preisig
Mar 1, 1986·Clinical Pharmacology and Therapeutics·C A BeachN Gerber
Nov 1, 1985·Scandinavian Journal of Gastroenterology·A WahlländerR Preisig
Apr 1, 1974·European Journal of Clinical Investigation·P B AndreasenN Tygstrup
Jan 1, 1981·Clinical Pharmacokinetics·B K Park, A M Breckenridge
Jul 15, 1982·Biochemical Pharmacology·D W Nebert, M Negishi
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E RennerR Preisig
Sep 1, 1984·British Journal of Clinical Pharmacology·E PeruccaA Richens
Jan 1, 1984·European Journal of Clinical Pharmacology·M LevyL Granit
Jan 1, 1984·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·C IoannidesD V Parke
Jul 1, 1984·Clinical Pharmacology and Therapeutics·E Zylber-KatzM Levy
Jan 1, 1981·European Journal of Clinical Pharmacology·H WietholtzR Preisig
Oct 1, 1982·European Journal of Clinical Investigation·W Röllinghoff, G Paumgartner
Dec 1, 1982·Drugs·R H Levy, K M Koch
Mar 1, 1983·The Journal of Pediatrics·K R RosenberryS J McGeady
Aug 1, 1981·British Journal of Clinical Pharmacology·L J Broughton, H J Rogers
Jan 1, 1981·European Journal of Clinical Pharmacology·R KnuttiC Schlatter
Mar 1, 1980·Digestive Diseases and Sciences·P V DesmondS Schenker

❮ Previous
Next ❯

Citations

Jan 1, 1991·European Journal of Clinical Pharmacology·T Zysset, H Wietholtz
Jul 12, 2008·Archives of Toxicology·Olavi PelkonenHannu Raunio
Mar 19, 2005·European Journal of Clinical Pharmacology·S KondoK Otani
Jun 1, 1991·Physiology & Behavior·R A Davidson, B D Smith
Jan 1, 1995·Journal of Hepatology·H WietholtzS Matern
Apr 15, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ehab S El DesokyJean-Pascal Siest
Apr 16, 2003·Journal of Pain and Symptom Management·Ahmad Beydoun, Misha-Miroslav Backonja
Nov 1, 1994·British Journal of Clinical Pharmacology·L BertilssonJ Benitez
Feb 1, 1995·Journal of Clinical Pharmacy and Therapeutics·O CalatayudP Ibáñez
Nov 1, 1990·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·B K Park, N R Kitteringham
May 7, 2013·Expert Opinion on Drug Metabolism & Toxicology·Vidya PereraAndrew J McLachlan
Jan 1, 1995·International Journal of Psychiatry in Medicine·W W Shen
Sep 21, 2013·Therapeutic Drug Monitoring·Norio Yasui-FurukoriYoshimasa Inoue
Jan 13, 2018·BMC Biology·Yong Fuga Li, Russ B Altman
Apr 1, 1996·Journal of Clinical Psychopharmacology·M J Byerly, C L DeVane
Nov 6, 2012·Expert Review of Clinical Pharmacology·Janne Hukkanen
Feb 1, 1995·Alimentary Pharmacology & Therapeutics·K U Petersen
Mar 10, 1998·British Journal of Clinical Pharmacology·A C ParkerI Choonara
May 16, 2019·Current Neurology and Neuroscience Reports·Prisca R Bauer, Josemir W Sander
Oct 29, 2020·Archives of Toxicology·Jukka HakkolaOlavi Pelkonen
Oct 27, 2009·Therapeutic Drug Monitoring·Satoshi YamadaTsukasa Uno

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.